Frankfurt
23.12.24
09:53 Uhr
8,600 Euro
+0,280
+3,37 %
+3,37 %
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 8,180 | 8,540 | 23.12. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.11. | Nexstim Oyj: Inside Information: Nexstim Plc and Brainlab AG initiate collaboration by signing development and distributorship cooperation agreement and agreeing on a maximum of EUR 5,095,000 equity investment into Nexstim | 109 | GlobeNewswire (Europe) | Company Announcement, Helsinki, 29 November 2024 at 9:15 AM (EET)
Inside Information: Nexstim Plc and Brainlab AG initiate collaboration by signing development and distributorship cooperation agreement... ► Artikel lesen | |
| 16.08. | Nexstim Oyj: Nexstim Plc Half-year Report January 1 - June 30, 2024 (unaudited) | 111 | GlobeNewswire (Europe) | Company announcement, Helsinki, August 16, 2024 at 9 am (EEST) NEXSTIM PLC HALF-YEAR REPORT JANUARY 1 - JUNE 30, 2024 (UNAUDITED) NEXSTIM CONTINUED TO GROW AND IMPROVED ITS PROFITABILITY IN THE FIRST... ► Artikel lesen | |
| NEXSTIM Aktie jetzt für 0€ handeln | |||||
| 07.06. | Nexstim Oyj: Insider Information: Nexstim Plc Announces Planned Alzheimer's Collaboration with Sinaptica Therapeutics, Inc. | 64 | GlobeNewswire (Europe) | Company announcement, Helsinki, 7 June 2024 at 9 AM (EEST) Insider Information: Nexstim Plc Announces Planned Alzheimer's Collaboration with Sinaptica Therapeutics, Inc. Nexstim Plc (NXTMH:HEX) ("Nexstim"... ► Artikel lesen |
3 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc. - 8-K, Current Report | ||
| VERU | 0,611 | -2,24 % | Veru (NASDAQ:VERU) Receives "Buy" Rating from HC Wainwright | ||
| AVINGER | 1,380 | +114,82 % | Avinger Inc - 8-K, Current Report | ||
| PROCEPT BIOROBOTICS | 83,46 | +2,85 % | PROCEPT BioRobotics Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance | SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| GENEDX | 76,75 | +0,46 % | GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights | STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the third... ► Artikel lesen | |
| NANO-X IMAGING | 7,015 | -0,78 % | Nano-X Imaging LTD.: Nanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary Indication | Nanox.ARC receives additional FDA clearance to produce tomographic images for general use, including pulmonary, intra-abdominal and paranasal indications, in addition to its previously cleared indication... ► Artikel lesen | |
| RXSIGHT | 34,305 | -0,82 % | RxSight cut to hold at Stifel on competition concerns | ||
| EUROPEAN WAX CENTER | 5,405 | +4,95 % | European Wax Center, Inc. Reports Third Quarter Fiscal Year 2024 Results | Reiterates fiscal 2024 financial outlook Updates fiscal 2024 outlook for net new centers Third Quarter Fiscal 2024 versus 2023 Net new centers increased 3.7% to 1,064 total centers in 45 statesSystem-wide... ► Artikel lesen | |
| 908 DEVICES | 1,880 | -1,05 % | 908 Devices stock hits 52-week low at $1.82 amidst market challenges | ||
| CASTLE BIOSCIENCES | 27,490 | +0,04 % | Castle Biosciences plant Markteinführung von Neurodermitis-Test bis Ende 2025 | ||
| CVRX | 12,835 | +2,68 % | CVRx, Inc.: CVRx Reports Third Quarter 2024 Financial and Operating Results | MINNEAPOLIS, Oct. 29, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation... ► Artikel lesen | |
| TALKSPACE | 3,040 | +1,33 % | Espresa Partners with Talkspace to Boost Employee Well-Being with Accessible Mental Health Benefits | Espresa has partnered with Talkspace to expand mental health support for employees. Through Espresa's platform, clients now have access to Talkspace's 5,000+ licensed therapists, offering secure, on-demand... ► Artikel lesen | |
| CLEARPOINT NEURO | 15,620 | +6,77 % | ClearPoint Neuro, Inc.: ClearPoint Neuro Announces FDA De Novo Marketing Authorization of SmartFlow Cannula for Direct Delivery of Gene Therapy to the Brain | Only Device Approved to Deliver First Disease-Modifying Treatment for AADC Deficiency in the United StatesSOLANA BEACH, CA / ACCESSWIRE / November 13, 2024 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the... ► Artikel lesen | |
| WORK MEDICAL TECHNOLOGY GROUP | 4,670 | -5,08 % | WORK Medical Technology Group LTD - F-1, Registration statement for certain foreign private issuers | ||
| ALIGNMENT HEALTHCARE | 10,610 | -0,93 % | Alignment Healthcare Reports Third Quarter 2024 Results | Reports $692.4 million in total revenue, up 51.6% year-over-year Increases Medicare Advantage membership, up 57.7% year-over-year to approximately 182,300 members, beating third-quarter and year-end... ► Artikel lesen |
NEXSTIM OYJ gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell +3,37 % bei einem Aktienkurs von 8,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEXSTIM OYJ finden Sie auf Wallstreet Online.
